search button
Open Access

Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer

  • Authors:
    • Geon Tae Ahn
    • Sun Kyung Baek
    • Jae Joon Han
    • Hong Jun Kim
    • Su Jin Jeong
    • Chi Hoon Maeng

  • View Affiliations

  • Published online on: July 17, 2020     https://doi.org/10.3892/ol.2020.11893
  • Article Number: 32

  • Copyright: © Ahn et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The effect of adjuvant chemotherapy (AC) for resected gastric cancer is well established; however, delays in treatment and its impact on clinical outcomes have not yet been determined. The current study analyzed the survival rates based on time interval (TI) between surgery and AC administration to evaluate a potential association between the two variables. Patients diagnosed with stage II‑III gastric adenocarcinoma between 2009 and 2016 at the Kyung Hee University Hospital were included. Patients' data including demographics, TNM stage, types of AC, and TI retrospectively collected from surgery to the start of AC. Patients were dichotomized based on the TI, which was predetermined at 3, 4, 5, 6, 7 or 8 weeks. Median disease‑free survival (DFS) and overall survival (OS) were analyzed according to TI. In total, 172 patients were identified. The median follow‑up duration was 40.8 (3‑109) months. The median TI was 4.1 (2.1‑9.8) weeks. DFS in patients with TI ≥4 weeks (n=106, 61.6%) was significantly lower compared with patients with TI <4 weeks (n=66, 38.4%), with a median DFS of TI < vs. ≥4 weeks of 8.1 vs. 6.0 years [hazard ratio (HR)=1.80, 95% confidence interval (CI): 1.067‑3.045, P=0.0277]. OS was also significantly reduced in patients with TI ≥4 weeks, favoring TI <4 weeks [median OS of TI < vs. ≥4 weeks: Not reached (NR) vs. 7.0 years, HR=2.15, 95% CI: 1.173‑3.939, P=0.0133]. Other predetermined TIs were not associated with survival outcomes. The current study demonstrated that AC within 4 weeks of surgery should be recommended for gastric cancer, and delays of >4 weeks may be detrimental to patients' survival.
View Figures
View References

Related Articles

Journal Cover

October-2020
Volume 20 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Ahn GT, Baek SK, Han JJ, Kim HJ, Jeong SJ and Maeng CH: Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer. Oncol Lett 20: 32, 2020.
APA
Ahn, G.T., Baek, S.K., Han, J.J., Kim, H.J., Jeong, S.J., & Maeng, C.H. (2020). Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer. Oncology Letters, 20, 32. https://doi.org/10.3892/ol.2020.11893
MLA
Ahn, G. T., Baek, S. K., Han, J. J., Kim, H. J., Jeong, S. J., Maeng, C. H."Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer". Oncology Letters 20.4 (2020): 32.
Chicago
Ahn, G. T., Baek, S. K., Han, J. J., Kim, H. J., Jeong, S. J., Maeng, C. H."Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer". Oncology Letters 20, no. 4 (2020): 32. https://doi.org/10.3892/ol.2020.11893